# Antibodies as Drugs

> **NIH NIH R13** · KEYSTONE SYMPOSIA · 2020 · $11,500

## Abstract

ABSTRACT
Support is requested for a Keystone Symposia conference entitled Antibodies as Drugs organized by Drs.
Pierre Bruhns, Patrick C. Wilson, Esther Breij and David P. Humphreys. The conference will be held in
Whistler, British Columbia from January 27-30, 2021.
Therapeutic antibodies continue to largely populate the list of top biologic drugs. They revolutionize the
treatment of pathologies falling into major disease areas, which include cancer, chronic inflammatory diseases,
allergy and infectious diseases. As more antibodies are being tested to treat an expanding number of
pathologies, there has also been a concomitant increase in the frequency of resistance and escape
mechanisms. Thus, researchers are exploring alternative concepts to prevent unresponsiveness or treat
resistant patients. Therefore, not only are new methodological and technological advances being developed,
paradigm-shifting concepts are being developed in order to face these challenges. This conference in the
Keystone Symposia series on Antibodies as Drugs aims to present the state-of-the-art in antibody
therapeutics, repertoires and deep learning, bispecific antibodies and engineering. This conference will provide
a forum for extensive interactions between investigators from both industry and academia. Goals of this
conference include discussion of recent breakthroughs in identifying therapeutics from patients, understanding
vaccination and mode of delivery, modalities for half-life extensions and involvement of complement in
antibody mode of action. It is anticipated that research in the field will showcase the rise of bispecific antibodies
and highlight the technologies to develop them, improve their functionalities, and boost clinical efficacies,
particularly in immune-oncology.

## Key facts

- **NIH application ID:** 10071067
- **Project number:** 1R13AI154980-01
- **Recipient organization:** KEYSTONE SYMPOSIA
- **Principal Investigator:** Thale Cross Jarvis
- **Activity code:** R13 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $11,500
- **Award type:** 1
- **Project period:** 2020-09-02 → 2022-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10071067

## Citation

> US National Institutes of Health, RePORTER application 10071067, Antibodies as Drugs (1R13AI154980-01). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10071067. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*